Federal Trade Commission (FTC) requests for information and documents have extended review of Lantheus Holdings, Inc. and Curium US Holdings LLC's planned acquisition, putting their first-half 2027 closing target through a longer antitrust process.
Each company received a formal Second Request for additional information and documentary materials on Oct. 21, Lantheus said in an Oct. 22 filing with the U.S. Securities and Exchange Commission. Under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, the waiting period cannot expire until 30 days after both parties substantially comply with the requests, unless the FTC ends it earlier. Other conditions in the merger agreement must also be met or waived for completion.
At closing, Curium would pay $102.50 per Lantheus share under the Aug. 3 merger agreement. Each share would also include a contingent value right (CVR) tied to commercial milestones, with an additional payment capped at $12. If the full amount is earned, consideration would reach $114.50 per share. Curium's announcement put the aggregate transaction value at up to approximately $8 billion.
Curium's Aug. 3 announcement said the combination would bring its global manufacturing and theranostics platform together with Lantheus' U.S. radiodiagnostics business. In the filing, both sides reaffirmed a closing goal for the first six months of 2027 and said they intend to answer the FTC quickly. The next timeline marker is substantial compliance by both companies, after which the 30-day period runs unless the FTC ends it sooner.
